~~<i id='AA8BCB2D88'><strike id='AA8BCB2D88'><tt id='AA8BCB2D88'><pre id='AA8BCB2D88'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：focus 2025-08-23 08:54:59 - browse：68

In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp. — Scott Olson/Getty Images

WASHINGTON — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.

The negotiated prices won’t take effect until 2026.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： More tobacco lobbyists active in statehouses

focus

knowledge

entertainment

hotspot

leisure time

MicroscopicimageofafemalemousefibroblastcellshowsXistRNAinred.WikimediaCommonsResearchershavelongkno

WSS

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Health care needs a new profession: neuroimaging counseling

New clues to why women have higher risk of autoimmune disorders

MultiPlan and major insurers sued for alleged medical price

10 reasons why health care startups fail

Investment in vaccine development is lagging, report finds

hotspot

comprehensive

focus

Medicare details structure of new drug price negotiation program

Merck CEO won’t testify in Senate, citing no expertise in drug prices

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

More tobacco lobbyists active in statehouses

Supreme Court strikes down use of affirmative action

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Element Biosciences CEO lays out genome sequencing strategy

Wildfire smoke exposes gaps in outdoor worker protections

Cell therapy fails to slow type 1 diabetes, but safety is established

knowledge

Reconstructing family trees of blood cells may help predict disease

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

White House pharmacy plagued with problems, investigation finds

After traumatic brain injury, life support decisions can use more time

Cell therapy fails to slow type 1 diabetes, but safety is established

entertainment

entertainment

hotspot

leisure time